Home / Resource Library / Pembrolizumab Plus ICE: Acceptable Salvage for Relapsed/Refractory Hodgkin LymphomaPembrolizumab Plus ICE: Acceptable Salvage for Relapsed/Refractory Hodgkin Lymphoma ASH 2021